Cytokinetics' heart disease drug meets main goal in late-stage study
ReutersMay 13, 2025 11:39 AM
May 13 (Reuters) - Cytokinetics CYTK.O said on Tuesday its experimental heart disease drug met the main goal in a late-stage study.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Warsh’s Fed Era Signals a Death Knell for QE, Jolting the $30 Trillion Treasury Market
With Warsh’s nomination, his past proposals for governing the Federal Reserve are being brought to the forefront. A central issue is the formulation of a new "1951 Accord" to restructure the relationship between the Fed and the Treasury. Analysts suggest such a move could impact the $30 trillion TreTradingKey
15 hours ago
Will TRON Reach $10? TRX Price Prediction 2026 and Canary Staked ETF Update
Explore TRON's 2026 outlook: Will TRX reach $10? Get the latest on the Canary Staked ETF SEC status, Justin Sun's strategy, and TRX price predictions through 2032.TradingKey
16 hours ago
Amazon Stock Predictions for 2026 to 2030: Will They Exceed Expectations and Achieve Major Long-Term Goals?
TradingKey - As we head into 2026, many investors are questioning where Amazon (AMZN) fits into the technology world.TradingKey
Fri, Feb 6
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.TradingKey
Fri, Feb 6
